Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study
Authors:
Open Access
- 1 January 2007
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 1
Abstract
Purpose: We conducted a pilot trial to assess the tolerability, clinical benefit and antitumoral efficacy of modified (hydrolysed) citrus pectin (MCP) in 49 patients with various solid tumors in an advanced state of progression. MCP are hydrolysed from polysaccharide pectin fibers, derived from citrus fruits and acting as a ligand for Galectin-3. Preclinical investigations revealed an efficient inhibition of tumor development and metastasis in various tumor models.Patients and Methods: The treatment consisted of the oral intake of 5 g MCP three times a day. One cycle of therapy was defined as 4 weeks of treatment. Objectives were clinical benefit (pain, functional performance, weight change), safety, tumor response (RESIST criteria) and quality of life (EORTC QLQ30).Results: 49 patients were enrolled, 29 patients were able to be evaluated for clinical benefit after 2 cycles of treatment. All patients tolerated the therapy well without any severe therapy-related adverse events. After 2 cycles of oral intake of MCP, 6/29 patients (20.7%) had an overall clinical benefit response associated with a stabilization or improvement of life quality. On an intent to treat basis 11/49 patients (22,5%) showed a stable disease (SD) after 2 cycles and 6/49 patients (12,3%) had a SD for a period longer than 24 weeks. One patient suffering from metastasized prostate carcinoma showed a 50% decrease in serum PSA level after 16 weeks of treatment associated with a significant increase of clinical benefit, quality of life and decrease in pain.Conclusion: MCP seems to have positive impacts especially regarding clinical benefit and life quality for patients with far advanced solid tumors. The presented preliminary data encourage us to further investigate the role of MCP in cancer prevention and treatment.Keywords
This publication has 25 references indexed in Scilit:
- Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS signaling pathwaysBiochemical Pharmacology, 2006
- The effect of modified citrus pectin on urinary excretion of toxic elementsPhytotherapy Research, 2006
- Prognostic Significance of Endogenous Adhesion/Growth-Regulatory Lectins in Lung CancerOncology, 2005
- Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot studyProstate Cancer and Prostatic Diseases, 2003
- Galectins: novel anti-inflammatory drug targetsExpert Opinion on Therapeutic Targets, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Inhibition of Spontaneous Metastasis in a Rat Prostate Cancer Model by Oral Administration of Modified Citrus PectinJNCI: Journal of the National Cancer Institute, 1995
- Soluble fiber and serum lipids: A literature reviewJournal of the American Dietetic Association, 1994
- Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus PectinJNCI: Journal of the National Cancer Institute, 1992
- The memorial pain assessment card. A valid instrument for the evaluation of cancer painCancer, 1987